Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Common Equity (2019 - 2025)

Harmony Biosciences Holdings' Common Equity history spans 7 years, with the latest figure at $870.2 million for Q4 2025.

  • For Q4 2025, Common Equity rose 32.02% year-over-year to $870.2 million; the TTM value through Dec 2025 reached $870.2 million, up 32.02%, while the annual FY2025 figure was $870.2 million, 32.02% up from the prior year.
  • Common Equity for Q4 2025 was $870.2 million at Harmony Biosciences Holdings, up from $835.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $870.2 million in Q4 2025 and bottomed at $107.9 million in Q1 2021.
  • The 5-year median for Common Equity is $474.2 million (2023), against an average of $458.3 million.
  • The largest annual shift saw Common Equity soared 126.21% in 2022 before it rose 11.01% in 2024.
  • A 5-year view of Common Equity shows it stood at $186.5 million in 2021, then soared by 115.99% to $402.8 million in 2022, then rose by 15.93% to $467.0 million in 2023, then surged by 41.15% to $659.2 million in 2024, then skyrocketed by 32.02% to $870.2 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Common Equity are $870.2 million (Q4 2025), $835.1 million (Q3 2025), and $773.1 million (Q2 2025).